Title Physician

Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer

NCT ID : NCT04851613
Protocol Number : LAE205INT3101
Phase : Phase Ib/II
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer

NCT ID : NCT04958785
Protocol Number : Gilead 586-6144
Phase : Phase II
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT ID : NCT04457596
Protocol Number : A011801
Phase : Phase III
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

NCT ID : NCT04647916
Protocol Number : SWOG S2007
Phase : Phase II
Location : Saint John's Cancer Institute
Parvin Peddi, M.D.

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

NCT ID : 01901094
Protocol Number : A011202
Phase : 3
Location : Santa Monica, CA
Alison Conlin, M.D.

The PREDICT Registry for DCIS Patients With DCISionRT Testing (PREDICT)

NCT ID : 03448926
Protocol Number : DCISionRT
Phase : N/A
Location : Santa Monica, CA
Janie Grumley, M.D.

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

NCT ID : 03927027
Protocol Number : A221702
Phase : 3
Location : Santa Monica, CA
Janie Grumley, M.D.

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

NCT ID : 04379570
Protocol Number : A191901
Phase : 4
Location : Santa Monica, CA
Janie Grumley, M.D.

EndoPredict® Extended Endocrine Trial (EXET)

NCT ID : 04016935
Protocol Number : ONC-010
Phase : N/A
Location : 181 S. Buena Vista St., Burbank, CA 91505
Erwin Grussie, M.D.

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

NCT ID : 04915755
Protocol Number : 213831
Phase : 3
Location : 181 S. Buena Vista St., Burbank, CA 91505
Erwin Grussie, M.D.

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

NCT ID : 04873362
Protocol Number : WO42633
Phase : 3
Location : 181 S. Buena Vista St., Burbank, CA 91505
Erwin Grussie, M.D.

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2
Location : Santa Monica, CA
Steven O' Day, M.D.